Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Latest updates in CAR-T therapy for follicular lymphoma

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an overview of recent advances in CAR-T therapy for follicular lymphoma (FL). Axicabtagene ciloleucel (axi-cel) was the first CAR-T therapy to be approved in FL. The promising results of the ZUMA-5 (NCT03105336) and ELARA (NCT03568461) studies are expected to lead to the approval of tisagenlecleucel (tisa-cel) in relapsed/refractory (R/R) FL. Further longitudinal data is required to better understand the impact of CAR-T therapy in patients with FL, as well as to determine which patients are most likely to benefit from this immunotherapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Disclosures

Consultant and/or advisory board member for AbbVie, Bayer, BeiGene, BMS, Janssen, Karyopharm, Kite Pharma/Gilead, Novartis, Nurix, and Takeda. Speaker for Kite Pharma/Gilead and he has received honoraria from Novartis. Research support from BMS, Calibr, CRISPR Therapeutics, Fate Therapeutics, Kite Pharma/Gilead, MorphoSys, Novartis, Tessa Therapeutics, and Xencor.